Nová definice status epilepticus a možnosti jeho farmakologické léčby
Authors:
O. Strýček 1; V. Šrámek 2
Authors‘ workplace:
I. neurologická klinika, Lékařská fakulta, Masarykova univerzita, Fakultní nemocnice u sv. Anny
1; Anesteziologicko-resuscitační klinika, Lékařská fakulta Masarykovy univerzity, Fakultní nemocnice u sv. Anny
2
Published in:
Anest. intenziv. Med., 29, 2018, č. 4, s. 207-216
Category:
Review Article
Overview
Status epilepticus is a life-threatening condition with a high mortality rate, requiring urgent therapy. To unify the views on this topic, a new definition has been proposed that reflects the patho-physiology better than the previous one. The new definition particularly highlights time as a major factor in the evolution of status epilepticus and points to the possibility of irreversible changes in the brain caused by the ongoing epileptic activity. The choice of a suitable drug is essential in treating status epilepticus. In addition to the traditional drugs (phenytoin, valproate), new drugs which promise significant benefits are emerging (levetiracetam, lacosamide). Some rescue treatment options (e.g. ketamine) are also mentioned. The choice of appropriately aggressive therapy is important. It is a common mistake to use one treatment guideline for all types of status epilepticus even though it does not fit the clinical picture and can even aggravate the patient’s condition. Non-convulsive status epilepticus in particular requires a different approach.
Keywords:
status epilepticus – definition – classification – therapy – antiepileptic drugs
Sources
1. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus-Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56:1515–1523.
2. Walton NY. Systemic effects of generalized convulsive status epilepticus. Epilepsia.1993;34:S54–S58.
3. Treiman DM, DeGiorgio CM, Salisbury S, et al. Subtle generalized convulsive status epilepticus. Epilepsia. 1984;25:653.
4. Dham BS, Hunter K, Rincon F. The epidemiology of status epilepticus in the United States. Neurocrit Care. 2014;20:476–483.
5. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46:1029–1035.
6. Laccheo I, Sonmezturk H, Bhatt AB, et al. Non-convulsive status epileptici and non-convulsive seizures in neurological ICU patients. Neurocrit Care. 2015;22:202–211.
7. Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry. 2005;76:534–539.
8. Kantanen AM, Reinikainen M, Parviainen I, et al. Incidence and mortality of super-refractory status epilepticus in adults. Epilepsy Behav. 2015;49:131–134.
9. DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995;12:316–325.
10. Shorvon SD, Ferlisi M. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135:2314–2328.
11. Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40:120–122.
12. Mazarati AM, Baldwin RA, Sankar R, Wasterlain CG. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res. 1998;814:179–185.
13. Alvarez V, Lee JW, Drislane FW, et al. Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: A multicenter comparison. Epilepsia. 2015;56:1275–1285.
14. Kolektiv autorů. Soubor minimálních diagnostických a terapeutických standardů u pacientů s epilepsií EpiStop 2017 [Internet]. Dostupné z http://www.clpe.cz/Epistandardy_2017_web.pdf
15. Talukdar B, Chakrabarty B. Efficacy of buccal midazolam comparedto intravenous diazepam in controlling convulsions in children: Arandomized controlled trial. Brain Dev. 2009;31:744–749.
16. Silbergleit R, Durkalski V, Lowenstein D, et al. NETT Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366:591–600.
17. Mohamed, W., Mahulikar, A., Rao, S., et al. Inadequacy of Benzodiazepine dosing in Status Epilepticus patients admitted to Neurointensive Care Unit (P4. 223). Neurology. 2017;88:P4–223.
18. Perucca E, Hebdige S, Frigo GM, et al. Interaction between phenytoin and valproic acid: plasma protein binding and metabolit effects. Clin Pharmacol Ther. 1980;28:779–789.
19. De Jong MJ, Karch AM, Lippincott's Critical Care Drug Guide. 1st edition. Philadelphia: Lippincott Williams & Wilkins, 2000.
20. Johannessen SI, Landmark CJ. Antiepileptic Drug Interactions – Principles and Clinical Implications. Current Neuropharmacology. 2010;8:254–267.
21. Annagur BB, Sayin AA, Akbaba N, Selvi Y. Valproic acid induced hyperammonemic encephalopathy: report of one case. In European Psychiatry. 2013;28:1.
22. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16:695–714.
23. Yoon HW, Giraldo EA, Wijdicks EF. Valproic acid and warfarin: an underrecognized drug interaction. Neurocrit Care. 2011;15:182–185.
24. Trinka E, Dobesberger J. New treatment options in status epilepticus: a critical review on levetiracetam. Ther Adv Neurol Dis. 2009;2:79–91.
25. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 200l;85:77–85.
26. Zaccara G, Perucca P, Loiacono G, et al. The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2013;54:66–74.
27. Cross SA, Curran MP. Lacosamide: in partial-onset seizures. Drugs. 2009;69:449–459.
28. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014;23:167–174.
29. Bleck T, Cock H, Chamberlain J, et al. The established status epilepticus trial 2013. Epilepsia. 2013;54:89–92.
30. Glauser T, Shinnar S, Gloss D, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Currents. 2016;16:48–61.
31. Young GB, Sharpe MD, Savard M, et al. Seizure detection with a commercially available bedside EEG monitor and the subhairline montage. Neurocrit Care. 2009;11:411–416.
32. Haider HA, Esteller R, Hahn CD, et al. Sensitivity of quantitative EEG for seizure identification in the intensive care unit. Neurology. 2016;87:935–944.
33. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med. 1998;338:970–976.
34. Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14:615–624.
35. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135:2314–2328.
36. Yeoman P, Hutchinson A, Byrne A, et al. Etomidate infusions for the control of refractory status epilepticus. Intensive Care Med. 1989;15:255–259.
37. Zeiler FA, Zeiler KJ, Teitelbaum J, et al. Modern inhalational anesthetics for refractory status epilepticus. Can J Neurol Sci. 2015;42:106–115.
38. Synowiec AS, Yandora KA, Yenugadhati V, et al. The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res. 2012;98:232–237.
39. Sivakumar S, Ibrahim M, Parker D Jr, et al. Clobazam: An effective add-on therapy in refractory status epilepticus. Epilepsia. 2015;56:e83–e89.
40. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: Still more questions than answers. Lancet neurology. 2011;10:922–930.
41. Wijdicks EF, Rabinstein AA, Hocker SE, Fugate JE. Neurocritical Care.2nd edition. New York: Oxford university press, 2016.
42. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239–1276.
43. Jacob S, Nair AB. An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs in R&D. 2016;16:303–316.
44. Sutter R, Semmlack S, Kaplan PW. Nonconvulsive status epilepticus in adults – insights into the invisible. Nat Rev Neurol. 2016;12:281–293.
45. Meierkord H, Holtkamp M. Non-convulsive status epilepticus in adults: clinical forms and treatment. Lancet Neurol. 2007;6:329–339.
46. Marchi NA, Novy J, Faouzi M, et al. Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med. 2015;43:1003–1009.
47. Ferguson M, Bianchi MT, Sutter R, et al. Calculating the risk benefit equation for aggressive treatment of non-convulsive status epilepticus. Neurocrit Care. 2013;18:216–227.
48. Rossetti AO, Oddo M, Logroscino G, Kaplan PW. Prognostication after cardiac arrest and hypothermia: a prospective study. Ann Neurol. 2010;67:301–307.
Labels
Anaesthesiology, Resuscitation and Inten Intensive Care Medicine Neurology Paediatrics General practitioner for children and adolescentsArticle was published in
Anaesthesiology and Intensive Care Medicine
2018 Issue 4
Most read in this issue
- Nová definice status epilepticus a možnosti jeho farmakologické léčby
- Patient transfers between healthcare facilities and referral healthcare facilities
- The use of ultrasound in interventional pain management
- Serum concentrations of calprotectin and cagranulin C in polytrauma patients